OPH

OPHIR HIGH CONVICTION FUND

Ophir is a specialist Australian investment management firm focused on high-performing small and mid-cap equity funds, identifying and investing in fast-growing businesses to deliver superior long-term returns for its investors.

Company Description

Ophir is a leading Australian investment management firm founded in 2012 by Andrew Mitchell and Steven Ng, specializing in small and mid-cap equity investments. The company is renowned for its focused approach to identifying and investing in high-quality, fast-growing emerging businesses with the potential to become household names. What sets Ophir apart is the founders’ commitment to their investment strategy, with Mitchell and Ng personally investing all their liquid personal wealth in the Ophir funds.

The firm manages multiple investment funds across Australian and global markets, including the Ophir Opportunities Fund, Ophir High Conviction Fund, Ophir Global Opportunities Fund, and Ophir Global High Conviction Fund. These funds have demonstrated exceptional performance, with the Opportunities Fund delivering a remarkable +24.0% p.a. since inception in August 2012, making it the best-performing Australian equities fund during that period. Ophir deliberately limits the capacity of its funds, believing that maintaining a smaller size is crucial to delivering exceptional returns.

Ophir serves a diverse range of investors, including institutions, family offices, private wealth groups, and individual investors. The company’s investment philosophy centers on identifying businesses with structural growth opportunities and the potential to disrupt existing market models. By maintaining a concentrated approach and deep research-driven strategy, Ophir aims to provide investors with access to high-quality investment opportunities that have the potential to generate significant long-term value across both Australian and global small and mid-cap markets.

OPHIR HIGH CONVICTION FUND

Scientists in advanced laboratory

Immuron (IMC) Wins FDA Approval for Phase 2 Trial

Immuron (ASX: IMC) Announces FDA Approval for IMM-529 Investigational New Drug Application In a material

Get Our "Big News" Alerts
Join 20,000+ subscribers today.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher